Assessment of therapeutic response of oropharyngeal and esophageal candidiasis in AIDS with use of a new clinical scoring system: Studies with D0870

Clinical Infectious Diseases

Volumn 28, Issue 3, 1999, Pages 587-596

  Hood, Stephen V ^a,b,c   Hollis, Sally ^a,b,c   Percy, Meryl ^a,b,c   Atkinson, Gill ^a,b,c   Williams, Keith ^a,b,c   Denning, David W ^a,b,c,d  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b LANCASTER UNIVERSITY   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

^d NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2,4 DIFLUOROPHENYL) 1 [3 [2 [4 (2,2,3,3 TETRAFLUOROPROPOXY)PHENYL]VINYL] 1,2,4 TRIAZOL 1 YL] 3 (1,2,4 TRIAZOL 1 YL) 2 PROPANOL; FLUCONAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; COLONY FORMING UNIT; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SENSITIVITY; DYSGEUSIA; DYSPHAGIA; FUNGUS CULTURE; HUMAN; PRIORITY JOURNAL; SCORING SYSTEM; SORE THROAT; THRUSH; TREATMENT OUTCOME; XEROSTOMIA;

EID: 0033046629     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/515149     Document Type: Article

References (23)

1. 1. Baily GG, Perry FM, Denning DW, Mandal BK. Fluconazole resistant candidosis in an HIV cohort. AIDS 1994;8:787-92.
2. 2. Coleman DC, Bennett DE, Sullivan DJ, et al. Oral Candida in HIV infection and AIDS: new perspectives/new approaches. Crit Rev Microbiol 1993;19:61-82.
3. 3. Hoover DR, Saah AJ, Bacellar H, et al. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. N Engl J Med 1993;329: 1922-6.
4. 4. Plettenburg A, Stoehr A, Hoffken G. Fluconazole therapy of oral candidiasis in HIV infected patients: results of a multicentre study. Infection 1994;22:118-23.
5. 5. Horsburgh CR, Kirkpatrick CH. Long term therapy of chronic mucocutaneous candidiasis with ketoconazole: experience with 21 patients. Am J Med 1983;74:23-9.
6. 6. Odds FC. Resistance of yeasts to azole-derivative antifungals. J Antimicrob Chemother 1993;31:463-71.
7. 7. Law D, Wardle HM, Ganguli LA, Keaney MGL, Denning DW. High prevalence of antifungal resistance in Candida spp. from patients with AIDS. J Antimicrob Chemother 1994;34:659-68.
8. 8. Ruhnke M, Eigler A, Tennagen I, Geiseler B, Engelmann E, Trautmann M. Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. J Clin Microbiol 1994;32:2092-8.
9. 9. Rodriguez-Tudela JL, Martinez-Suarez JV, Dronda F, Laguna F, Chaves F, Valencia E. Correlation of in-vitro susceptibility test results with clinical response: a study of azole therapy in AIDS patients. J Antimicrob Chemother 1995;35:793-804.
10. 10. Samaranayake LP, Holmstrup P. Oral candidiasis and human immunodeficiency virus infection. J Oral Pathol Med 1989;18:554-64.
11. 11. Laine L, Bonacini M. Oesophageal disease in human immunodeficiency virus infection. Arch Intern Med 1994;154:1577-82.
12. 12. Diz Dios P, Ocampo Hermida A, Miralles Alvarez C, Iglesias Martin I, Otero Varela I. Fluconazole-resistant candidosis in HIV-infected patients. AIDS 1995;9:809-10.
13. 13. Wardle H, Moore C, Law D, Mason C, Denning DW. In vitro activity of D0870 compared with those of other azoles against fluconazole resistant Candida spp. Antimicrob Agents Chemother 1995;39:868-71.
14. 14. Pfaller MA, Bale MJ, Buschelman B, Rhomberg P. Antifungal activity of a new triazole, D0870, compared with four other antifungal agents tested against clinical isolates of Candida and Torulopsis glabrata. Diagn Microbiol Infect Dis 1994;19:75-80.
15. 15. Edwards JR, Naim K, Megson GM, Shepherd GL, Hughes GL. Activity of D0870 against C. albicans and C. neoformans showing reduced susceptibility to fluconazole [abstract no 375]. In: Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans). Washington, DC: American Society for Microbiology, 1993.
16. 16. De Wit S, Dupont B, Cartledge JD, et al. A dose comparison study of a new triazole antifungal (D0870) in HIV patients with oral candidiasis. AIDS 1997; 11:759-64.
17. 17. Cartledge JD, Denning DW, Dupont D, et al. Treatment of HIV-related fluconazole-resistant oral candidosis with D0870, a new triazole antifungal. AIDS 1998;12:411-6.
18. 18. Megson GM, Hughes GD, Edwards JR. A broth microdilution method for assessing the fungistatic and fungicidal activity of D0870, a new triazole agent [abstract]. Trends in Invasive Fungal Infections II (Manchester, United Kingdom). 1993.
19. 19. Hood SV, Denning DW. Treatment of fungal infection in AIDS. J Antimicrob Chemother 1996;37(suppl B):71-85.
20. 20. Cartledge JD, Midgley J, Youle M, Gazzard BG. Itraconazole cyclodextrin solution - effective treatment for HIV related candidosis unresponsive to other azole therapy. J Antimicrob Chemother 1994; 33:1071-3.
21. 21. Eichel M, Just-Nubling G, Helm EB, Stille W. Itraconazole supension in the treatment of HIV-infected patients suffering from fluconazole-resistant oropharyngeal and oesophageal candidosis. Mycoses 1996; 39(suppl 1):102-6.
22. 22. Hood S, Evans J, Bond J, Wilkins E, Denning D. The treatment of oropharyngeal candidiasis in HIV-infected patients with oral amphotericin B suspension. AIDS Patient Care and STDs 1998;8:625-7.
23. 23. Plettenburg A, Stoehr A, Hoffken G, et al. Fluconazole therapy of oral candidiasis in HIV infected patients: results of a multicentre study. Infection 1994;22:118-23.